We have shown that BCR pathway inhibitors, such as idelalisib and ibrutinib, function by blocking PI3Kδ and thereby increasing genomic instability in B cells, including in CLL models [9,10]. Here, BCR is linked to B-cell chronic lymphocytic leukemia.